Nirogacestat hydrobromide

Drug Overview

Nirogacestat hydrobromide (brand name Ogsiveo) is an orally bioavailable, small-molecule gamma-secretase inhibitor. It is a first-in-class targeted therapy specifically designed to inhibit the Notch signaling pathway, which plays a pivotal role in the development and growth of certain types of soft tissue tumors.

In the clinical landscape of March 2026, nirogacestat is recognized as a breakthrough treatment. In November 2023, it became the first drug to receive FDA approval for the treatment of progressing desmoid tumors (also known as aggressive fibromatosis). More recently, in January 2026, the UK’s MHRA also approved this indication. While desmoid tumors are technically non-cancerous (benign) because they do not spread to distant organs, they are locally aggressive, infiltrating nearby muscles and nerves, which can lead to chronic pain, physical disfigurement, and loss of mobility.

• Generic Name: Nirogacestat hydrobromide.
• Brand Name: Ogsiveo.
• Drug Class: Gamma-secretase Inhibitor; Antineoplastic Agent.
• Mechanism: Inhibition of the gamma-secretase enzyme complex to block Notch receptor activation.
• Route of Administration: Oral (Tablet).
• FDA Approval Status: FDA-approved (November 27, 2023) for adult patients with progressing desmoid tumors who require systemic treatment.

What Is It and How Does It Work? (Mechanism of Action)

Nirogacestat targets the molecular “machinery” that drives the survival of desmoid tumor cells.

1. Gamma-Secretase Inhibition

Gamma-secretase is an enzyme complex located within the cell membrane. It acts as a pair of “molecular scissors” that cuts various proteins, including the Notch receptor.

• Cleavage Blockade: When a Notch receptor is triggered by a neighboring cell, gamma-secretase normally cleaves it, releasing a fragment called the Notch Intracellular Domain (NICD).
• Stopping the Signal: Nirogacestat binds to and inhibits gamma-secretase, preventing the release of NICD. Without this fragment, the Notch signal cannot reach the cell’s nucleus to “turn on” genes that promote tumor growth and survival.

2. Disruption of Fibrosis and Adhesion

In addition to Notch, gamma-secretase processes other proteins involved in cell-to-cell communication and adhesion (like CD44). By blocking these secondary targets, nirogacestat may further reduce the infiltrative and “sticky” nature of desmoid tumors, making them less likely to invade surrounding healthy tissue.

FDA-Approved Clinical Indications

As of 2026, nirogacestat is primarily indicated for:

• Progressing Desmoid Tumors: For adult patients with tumors that are growing, causing symptoms, or are in sensitive locations where surgery is not an option.

Investigational Uses (Active Research)

Beyond desmoid tumors, nirogacestat is being studied in combination with other agents for:

• Multiple Myeloma: Used in combination with BCMA-targeted therapies (like CAR-T or bispecific antibodies). Gamma-secretase normally “sheds” BCMA from the surface of myeloma cells; by inhibiting this enzyme, nirogacestat keeps more BCMA on the cell surface, potentially making the immunotherapy more effective.
• Other Solid Tumors: Early-phase trials are exploring its use in certain breast and ovarian cancers with overactive Notch signaling.

Dosage and Administration Protocols

Nirogacestat is taken as a tablet, typically twice a day.

Clinical Efficacy and Research Results

The approval of nirogacestat was based on the landmark DeFi Phase 3 clinical trial.

• PFS Benefit: The trial showed a 71% reduction in the risk of disease progression or death compared to a placebo.
• Objective Response Rate (ORR): 41% of patients saw their tumors shrink significantly (compared to 8% in the placebo group), with 7% experiencing a complete disappearance of the tumor.
• Long-Term Durability (2025-2026 update): Follow-up data presented at the ESMO 2025 Congress showed that these responses are durable, with some patients maintaining stable disease or continued shrinkage for over 4 years on continuous therapy.
• Quality of Life: Patients consistently reported early and sustained reductions in tumor-related pain and improvements in physical functioning and general health.

Safety Profile and Side Effects

While highly effective, nirogacestat has a distinct side-effect profile related to its effect on the Notch pathway.

Common Side Effects (>25%):

• Diarrhea: The most frequent side effect (occurring in 84% of patients). It is often manageable with anti-diarrheal meds like loperamide.
• Skin Rash: Various types of rashes or dry skin.
• Nausea and Fatigue: General systemic tiredness.
• Stomatitis: Inflammation or sores in the mouth.
• Alopecia: Thinning or loss of hair.

Serious Risks and Specific Concerns:

• Ovarian Toxicity: A major concern for women of childbearing age; nirogacestat can cause premature menopause or changes in the menstrual cycle (occurring in ~75% of women in trials). While many recover after stopping the drug, the long-term effect on fertility is still being studied.
• Electrolyte Abnormalities: Frequently causes hypophosphatemia (low phosphate) and hypokalemia (low potassium).
• Hepatotoxicity: Elevation in liver enzymes, requiring regular blood monitoring.
• Non-Melanoma Skin Cancer: There is a slightly increased risk of developing new, non-melanoma skin cancers during treatment.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, nirogacestat is a critical tool for studying “Cell Fate Decisions.” Because Notch signaling is the master regulator that tells a stem cell whether to become a muscle, nerve, or skin cell, researchers use nirogacestat to manipulate these pathways in the lab. In 2026, there is also intense focus on “Gamma-Secretase Shedding.” Scientists are investigating how nirogacestat can be used to prevent the loss of therapeutic targets from the surface of cancer cells, which could revolutionize how we combine targeted drugs with CAR-T cell therapy.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Liver Function and Electrolytes: Baseline blood tests are mandatory.
• Fertility Consultation: Women of childbearing potential should discuss egg freezing or other fertility preservation options before starting.
• Skin Exam: A baseline skin check to monitor for any new skin lesions during treatment.

“Do’s and Don’ts” List:

• DO have loperamide on hand before your first dose to manage potential diarrhea.
• DO report any changes in your menstrual cycle or new skin growths to your doctor immediately.
• DON’T consume grapefruit products or Seville oranges, as they can dangerously increase the levels of nirogacestat in your blood.
• DON’T take proton pump inhibitors (PPIs) like omeprazole without checking with your doctor, as they may reduce the drug’s effectiveness.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Nirogacestat (Ogsiveo) is a potent targeted therapy that must be managed by an oncologist. Always consult with your healthcare provider regarding your specific diagnosis, potential side effects, and fertility concerns.